{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:29:22Z","timestamp":1793410162718,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Prim. Care Respir. Med."],"DOI":"10.1038\/s41533-025-00456-4","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:13:43Z","timestamp":1761542023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Refining mild asthma phenotyping with FeNO: a population-based evaluation"],"prefix":"10.1038","volume":"35","author":[{"given":"Charmaine J. M.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Kathrin","family":"Breyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel F. M.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robab","family":"Breyer-Kohansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"456_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord, I. D. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380, 651\u2013659 (2012).","journal-title":"Lancet"},{"key":"456_CR2","unstructured":"2023 GINA Main Report. Global Initiative for Asthma - GINA https:\/\/ginasthma.org\/2023-gina-main-report\/."},{"key":"456_CR3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/thoraxjnl-2018-211540","volume":"73","author":"HL Petsky","year":"2018","unstructured":"Petsky, H. L., Cates, C. J., Kew, K. M. & Chang, A. B. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax 73, 1110\u20131119, https:\/\/doi.org\/10.1136\/thoraxjnl-2018-211540 (2018).","journal-title":"Thorax"},{"key":"456_CR4","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","volume":"160","author":"LG Heaney","year":"2021","unstructured":"Heaney, L. G. et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest 160, 814\u2013830 (2021).","journal-title":"Chest"},{"key":"456_CR5","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1814917","volume":"380","author":"SC Lazarus","year":"2019","unstructured":"Lazarus, S. C. et al. Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N. Engl. J. Med 380, 2009\u20132019 (2019).","journal-title":"N. Engl. J. Med"},{"key":"456_CR6","first-page":"618","volume":"8","author":"R Louis","year":"2020","unstructured":"Louis, R. et al. Bronchodilation test with inhaled salbutamol versus bronchial methacholine challenge to make an asthma diagnosis: do they provide the same information?. J. Allergy Clin. Immunology: Pract. 8, 618\u2013625.e8 (2020).","journal-title":"J. Allergy Clin. Immunology: Pract."},{"key":"456_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2188\/jea.JE20180039","volume":"29","author":"R Breyer-Kohansal","year":"2019","unstructured":"Breyer-Kohansal, R. et al. The LEAD (Lung, heart, social, body) study: objectives, methodology, and external validity of the population-based cohort study. J. Epidemiol. 29, 315\u2013324 (2019).","journal-title":"J. Epidemiol."},{"key":"456_CR8","doi-asserted-by":"publisher","first-page":"e074819","DOI":"10.1136\/bmj-2023-074819","volume":"384","author":"GS Collins","year":"2024","unstructured":"Collins, G. S. et al. Evaluation of clinical prediction models (part 1): from development to external validation. BMJ 384, e074819 (2024).","journal-title":"BMJ"},{"key":"456_CR9","first-page":"4353","volume":"9","author":"M Kerkhof","year":"2021","unstructured":"Kerkhof, M. et al. Asthma phenotyping in primary care: applying the international severe asthma registry eosinophil phenotype algorithm across all asthma severities. J. Allergy Clin. Immunology: Pract. 9, 4353\u20134370 (2021).","journal-title":"J. Allergy Clin. Immunology: Pract."},{"key":"456_CR10","doi-asserted-by":"publisher","first-page":"00169","DOI":"10.1183\/23120541.00169-2020","volume":"6","author":"H Nekoee","year":"2020","unstructured":"Nekoee, H. et al. Are type-2 biomarkers of any help in asthma diagnosis?. ERJ Open Res 6, 00169\u201302020 (2020).","journal-title":"ERJ Open Res"},{"key":"456_CR11","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.2174\/1389450119666180212120012","volume":"19","author":"K Kostikas","year":"2018","unstructured":"Kostikas, K., Brindicci, C. & Patalano, F. Blood eosinophils as biomarkers to drive treatment choices in asthma and COPD. Curr. Drug Targets 19, 1882 (2018).","journal-title":"Curr. Drug Targets"},{"key":"456_CR12","first-page":"960","volume":"12","author":"R Covar","year":"2024","unstructured":"Covar, R. et al. Association of sputum eosinophilia with easily measured type-2 inflammatory biomarkers in untreated mild persistent asthma. J. Allergy Clin. Immunology: Pract. 12, 960\u2013969.e6 (2024).","journal-title":"J. Allergy Clin. Immunology: Pract."},{"key":"456_CR13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1081-1206(10)60480-2","volume":"100","author":"IL Bernstein","year":"2008","unstructured":"Bernstein, I. L. et al. Allergy diagnostic testing: an updated practice parameter. Ann. Allergy, Asthma Immunol. 100, S1\u2013S148 (2008).","journal-title":"Ann. Allergy, Asthma Immunol."},{"key":"456_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jaci.2005.03.025","volume":"116","author":"CP McSharry","year":"2005","unstructured":"McSharry, C. P. et al. Short and long-term effects of cigarette smoking independently influence exhaled nitric oxide concentration in asthma. J. Allergy Clin. Immunol. 116, 88\u201393 (2005).","journal-title":"J. Allergy Clin. Immunol."},{"key":"456_CR15","doi-asserted-by":"publisher","first-page":"106066","DOI":"10.1016\/j.rmed.2020.106066","volume":"170","author":"AE Sprio","year":"2020","unstructured":"Sprio, A. E. et al. The influence of smoking on asthma in the real-life. Respiratory Med. 170, 106066 (2020).","journal-title":"Respiratory Med."},{"key":"456_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/cea.12669","volume":"46","author":"J Giovannelli","year":"2016","unstructured":"Giovannelli, J. et al. Both exhaled nitric oxide and blood eosinophil count were associated with mild allergic asthma only in non-smokers. Clin. Exp. Allergy 46, 543\u2013554 (2016).","journal-title":"Clin. Exp. Allergy"},{"key":"456_CR17","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1164\/rccm.202304-0642ST","volume":"207","author":"A Mohan","year":"2023","unstructured":"Mohan, A. et al. Questions in mild asthma: an official american thoracic society research statement. Am. J. Respir. Crit. Care Med 207, e77\u2013e96 (2023).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"456_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2147\/JAA.S430183","volume":"16","author":"J Naftel","year":"2023","unstructured":"Naftel, J. et al. How does mild asthma differ phenotypically from difficult-to-treat asthma?. J. Asthma Allergy 16, 1333\u20131345 (2023).","journal-title":"J. Asthma Allergy"},{"key":"456_CR19","doi-asserted-by":"publisher","first-page":"00359","DOI":"10.1183\/23120541.00359-2019","volume":"6","author":"JM FitzGerald","year":"2020","unstructured":"FitzGerald, J. M. et al. The burden of exacerbations in mild asthma: a systematic review. ERJ Open Res 6, 00359\u201302019 (2020).","journal-title":"ERJ Open Res"},{"key":"456_CR20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","volume":"146","author":"2020 Focused Updates to the Asthma Management Guidelines","year":"2020","unstructured":"2020 Focused Updates to the Asthma Management Guidelines A report from the national asthma education and prevention program coordinating committee expert panel working group. J. Allergy Clin. Immunol. 146, 1217\u20131270 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"456_CR21","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1378\/chest.129.6.1492","volume":"129","author":"AF Gelb","year":"2006","unstructured":"Gelb, A. F., Taylor, C. F., Shinar, C. M., Gutierrez, C. & Zamel, N. Role of Spirometry and Exhaled Nitric Oxide To Predict Exacerbations in Treated Asthmatics. CHEST 129, 1492\u20131499 (2006).","journal-title":"CHEST"},{"key":"456_CR22","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.21037\/jtd.2019.05.47","volume":"11","author":"Y Yuan","year":"2019","unstructured":"Yuan, Y. et al. Fractional exhaled nitric oxide was not associated with the future risk of exacerbations in Chinese asthmatics: a non-interventional 1-year real-world study. J. Thorac. Dis. 11, 2438\u20132447 (2019).","journal-title":"J. Thorac. Dis."},{"key":"456_CR23","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","volume":"184","author":"RA Dweik","year":"2011","unstructured":"Dweik, R. A. et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am. J. Respir. Crit. Care Med 184, 602\u2013615 (2011).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"456_CR24","doi-asserted-by":"publisher","first-page":"2442662","DOI":"10.1080\/25310429.2024.2442662","volume":"31","author":"C Bal","year":"2025","unstructured":"Bal, C. et al. Fractional exhaled nitric oxide in a respiratory healthy general population through the lifespan. Pulmonology 31, 2442662 (2025).","journal-title":"Pulmonology"},{"key":"456_CR25","first-page":"100253","volume":"3","author":"M Yamada","year":"2024","unstructured":"Yamada, M. et al. Fractional exhaled nitric oxide distribution and its relevant factors in the general adult population and its healthy subpopulation. J. Allergy Clin. Immunology: Glob. 3, 100253 (2024).","journal-title":"J. Allergy Clin. Immunology: Glob."},{"key":"456_CR26","doi-asserted-by":"publisher","first-page":"1901874","DOI":"10.1183\/13993003.01874-2019","volume":"55","author":"S Hartl","year":"2020","unstructured":"Hartl, S. et al. Blood eosinophil count in the general population: typical values and potential confounders. Eur. Respiratory J. 55, 1901874 (2020).","journal-title":"Eur. Respiratory J."},{"key":"456_CR27","doi-asserted-by":"publisher","first-page":"2004590","DOI":"10.1183\/13993003.04590-2020","volume":"59","author":"VS Benson","year":"2022","unstructured":"Benson, V. S. et al. Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. Eur. Respiratory J. 59, 2004590 (2022).","journal-title":"Eur. Respiratory J."}],"container-title":["npj Primary Care Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41533-025-00456-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-025-00456-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-025-00456-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:06:05Z","timestamp":1761847565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41533-025-00456-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1038\/s41533-025-00456-4","relation":{},"ISSN":["2055-1010"],"issn-type":[{"value":"2055-1010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no competing interests relevant to the manuscript. R.B.-K. and M.-K.B. reports consulting fees from AstraZeneca, Menarini Pharma, Sanofi, B\u00f6hringer Ingelheim, Novartis Pharma and Glaxo Smith Kline for advisory board members outside the submitted work. C.J.M.L and E.F.M.W. have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}